Adding a Nutrition Formula to Standard Medicines for Active Crohn's Disease
Tests a drinkable nutrition formula alongside advanced medicines in adults with active Crohn's disease.
Plain-language title generated from the registry record
Registry title: Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
Key facts
- Where
- Austin, Beverly Hills, Chapel Hill, New Brunswick, and Philadelphia, United StatesSee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07356232, who can take part
Where in United States
- University of Texas at Austin, Dell MedAustin, United StatesNo longer taking part
- Cedars-Sinai Medical CenterBeverly Hills, United StatesNo longer taking part
- University of North CarolinaChapel Hill, United StatesNo longer taking part
- Rutgers UniversityNew Brunswick, United StatesNo longer taking part
- University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- James Lewis
- Trial code
- NCT07356232
- Record updated
- 3 November 2026
- Original description
This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy. Our central hypothesis is that combination therapy of PEN and pharmacologic therapy is more efficacious than pharmacologic therapy alone and can be well-tolerated for patients. Participants will choose to either include PEN along with starting their advanced therapy or will choose not to include PEN. 80 participants will be recruited from 15 sites across the United States.Read full original descriptionShow less
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy. Our central hypothesis is that combination therapy of PEN and pharmacologic therapy is more efficacious than pharmacologic therapy alone and can be well-tolerated for patients. Participants will choose to either include PEN along with starting their advanced therapy or will choose not to include PEN. 80 participants will be recruited from 15 sites across the United States.
Inclusion: Ability to provide informed consent; A confirmed diagnosis of Crohn's disease; Plan to start one advanced Crohn's Disease therapy (anti-TNF, anti-IL12/IL23, anti-IL23, anti-alpha 4 beta 7, JAK inhibitor); If taking aminosalyilates, methotrexate or thiopurines, participant must be on a stable does for at least 8 weeks prior to screening. Methotrexate, aminosalicylates and thiopurines are permitted to be continued with the advanced therapy if on stable dose for at least 8 weeks. Methotrexate or thiopurines may be initiated within 1 week of starting the advanced pharmacologic therapy; Active disease defined by at least one of the criteria from group A AND one from group B; Group A; Short Crohn's Disease Activity Index (sCDAI) score >175, and if taking corticosteroids, dose cannot exceed 30 mg for prednisone or 9 mg for budesonide,; sCDAI < 175 and on 10- 30 mg of prednisone (or 6-9 mg of budesonide) at a stable dose for 2 weeks. Must have experienced worsening of symptoms with attempts to taper to a lower dose of steroids in 3 months prior to screening; Group B; Fecal calprotectin at baseline ≥ 300 ug/gr; Active disease seen at colonoscopy within 8 weeks of the screening visit. Active disease requires presence of mucosal breaks including either diffuse scattered erosions or at least one ulcer (>5mm diameter); Active disease on cross-sectional imaging (CT scan, MRI or ultrasound) within 8 weeks of the screening visit (evidence of acute inflammation, such as ulceration or bowel wall thickening with restricted diffusion).
Exclusion: Previous total colectomy; Short gut syndrome from prior surgeries; Consuming parenteral nutrition for more than 350 calories per day in the two weeks prior to screening; Having been on the Crohn's Disease Exclusion Diet (CDED) in the 2 weeks prior to screening; Plan to receive two simultaneously administered advanced therapies; Planning to start a new medication in the same class as the medication currently taking. This does not include a switch from Ustekinumab to anti-IL23 drugs; Impending need for CD surgery per investigator; Starting a new medication for Crohn's disease other than steroids in the 8 weeks prior to the screening visit; Has not consumed food in the last 6 days prior to screening; Starting an accelerated (non-FDA approved) dose of advanced therapy; Diabetes mellitus requiring therapy with medication; Known allergy to any ingredient in the Kate Farms formula; Untreated C. difficile infection with the last 8 weeks; Pregnancy or breast feeding; Presence of an ostomy; Symptomatic stricture or stricture inducing bowel dilation (>3cm) as per local investigator; >4 very soft or liquid bowel movements per day when feeling well; Unable to complete online surveys; Unable to receive shipments of PEN formula; At time of screening, participant is taking both Prednisone and Budesonide.